Dr. Michelle A. Cholankeril, MD

Dr. Cholankeril practices at St. Joseph's University Medical Center in Paterson, New Jersey, part of Sisters of Charity of Saint Elizabeth.

Dr. Cholankeril's NPI, 1801056155, was assigned on June 11, 2008. Dr. Cholankeril holds New Jersey license 25MA08538200.

Dr. Cholankeril's primary practice is St. Joseph's University Medical Center, at 703 Main St, Paterson, NJ 07503 in Passaic County. The practice phone is (973) 754-2010.

Dr. Cholankeril's primary practice is St. Joseph's University Medical Center in Paterson, New Jersey, part of Sisters of Charity of Saint Elizabeth.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cholankeril practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Cholankeril's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Cholankeril is licensed in New Jersey.

CMS data shows 130 Medicare services from Dr. Cholankeril across 4 procedure codes in 2024, for 82 Medicare patients. Medicare paid $10,838 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 82 Medicare patients who saw Dr. Cholankeril in 2024. The largest group is 75 to 84, with 30 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 41% are also on Medicaid. Their average risk score is 2.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cholankeril's median patient age at 75, with 38% women.

In 2024, Dr. Cholankeril wrote 449 Medicare Part D claims for 103 patients. 86% of them were for generic drugs. CMS names the drug for 259 of them, across 11 drugs with 11 or more claims each, at $79,844 in total drug cost. In 2023, CMS named 512 claims across 25 drugs.

CMS Open Payments shows 345 general payments to Dr. Cholankeril from 42 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 98% of the total. Bristol-Myers Squibb Company paid the most, $604.